Literature DB >> 28677766

Human decidua mesenchymal stem cells regulate decidual natural killer cell function via interactions between collagen and leukocyte‑associated immunoglobulin‑like receptor 1.

Qiang Fu1, Xuejing Man2, Min Yu3, Yongli Chu2, Xiying Luan1, Hailan Piao3, Jiangnan Xue1, Changzhu Jin1.   

Abstract

The development of maternal tolerance to the fetal allograft in critical for the maintenance of the pregnancy, and it is accompanied by the development of a special decidual natural killer (dNK) cell tolerance phenotype. To understand the factors that influence dNK cells during early pregnancy, the present study aimed to identify mesenchymal stem cells (MSCs) from human first‑trimester deciduas, termed decidual MSCs (DMSCs), and to investigate the effect of DMSCs on the regulation of dNK cells via collagen. Decidual samples were collected from women with normal pregnancy that had undergone elective vaginal surgical terminations at 6‑9 weeks gestation. DMSCs derived from human decidual tissues were cultured under differentiation conditions to examine their multipotent differentiation capacities, and the expression of MSC‑specific markers, including cluster of differentiation (CD)44, CD73, CD105, CD90, CD34, CD31, CD14, CD45, CD11b and human leukocyte antigen‑antigen D related, was determined. dNK cells were co‑cultured with DMSCs in order to examine the effect of DMSCs on the tolerance phenotype of dNK cells. The expression of cell surface molecules, natural cytotoxicity triggering receptor 3 and killer cell immunoglobulin‑like receptor (KIR) 2DL1, and the secretion of cytokines, including interferon‑γ, tumor necrosis factor (TNF)‑α, interleukin (IL)‑10, IL‑4 and perforin, were examined by flow cytometry analysis. To determine whether the regulation of dNK cells by DMSCs was mediated by collagen, DMSCs were pre‑treated with human recombinant leukocyte‑associated immunoglobulin‑like receptor (LAIR)‑2 and transfected with pScoR‑GFP‑hP4H to inhibit the interaction between LAIR‑1 and collagen. The present results demonstrated that collagen produced by DMSCs increased the expression of KIR2DL1 and IL‑4, decrease the expression of NKp30 and TNF‑α. In conclusion, the results of the present study demonstrated that DMSCs may be cultured in vitro for prolonged periods, whilst retaining the ability to differentiate into different cell lineages. In addition, DMSCs may modulate the function of dNK cells via the interaction between collagen and LAIR‑1.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28677766     DOI: 10.3892/mmr.2017.6921

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  9 in total

1.  Immunological impact of Wharton's Jelly mesenchymal stromal cells and natural killer cell co-culture.

Authors:  Mehdi Najar; Mohammad Fayyad-Kazan; Nathalie Meuleman; Dominique Bron; Hussein Fayyad-Kazan; Laurence Lagneaux
Journal:  Mol Cell Biochem       Date:  2018-01-30       Impact factor: 3.396

2.  Mesenchymal stromal cells of the bone marrow and natural killer cells: cell interactions and cross modulation.

Authors:  Mehdi Najar; Mohammad Fayyad-Kazan; Nathalie Meuleman; Dominique Bron; Hussein Fayyad-Kazan; Laurence Lagneaux
Journal:  J Cell Commun Signal       Date:  2018-01-19       Impact factor: 5.782

3.  IL-27 Promotes Human Placenta-Derived Mesenchymal Stromal Cell Ability To Induce the Generation of CD4+IL-10+IFN-γ+ T Cells via the JAK/STAT Pathway in the Treatment of Experimental Graft-versus-Host Disease.

Authors:  Junzhu Yi; Zhenghua Chen; Fenghuang Xu; ZhuoYa Wang; Aiping Zhang; Tongshen Liu; Nannan Zhao; Yanlian Xiong; Guosheng Jiang; Junjie Ma; Xiying Luan
Journal:  J Immunol       Date:  2019-01-16       Impact factor: 5.422

Review 4.  The pathological and therapeutic roles of mesenchymal stem cells in preeclampsia.

Authors:  Sanshan Jin; Canrong Wu; Ming Chen; Dongyan Sun; Hua Zhang
Journal:  Front Med (Lausanne)       Date:  2022-07-28

Review 5.  Immunomodulatory effects of mesenchymal stem cells in peripheral nerve injury.

Authors:  Xiangling Li; Yanjun Guan; Chaochao Li; Tieyuan Zhang; Fanqi Meng; Jian Zhang; Junyang Li; Shengfeng Chen; Qi Wang; Yi Wang; Jiang Peng; Jinshu Tang
Journal:  Stem Cell Res Ther       Date:  2022-01-15       Impact factor: 6.832

Review 6.  Mesenchymal stem cells and natural killer cells interaction mechanisms and potential clinical applications.

Authors:  Batol Abbasi; Karim Shamsasenjan; Majid Ahmadi; Seyedeh Ameneh Beheshti; Mahshid Saleh
Journal:  Stem Cell Res Ther       Date:  2022-03-07       Impact factor: 6.832

Review 7.  Emerging roles of mesenchymal stem cell therapy in patients with critical limb ischemia.

Authors:  Zeinab Shirbaghaee; Mohammad Hassani; Saeed Heidari Keshel; Masoud Soleimani
Journal:  Stem Cell Res Ther       Date:  2022-09-06       Impact factor: 8.079

Review 8.  Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress.

Authors:  Xiaomo Wu; Ju Jiang; Zhongkai Gu; Jinyan Zhang; Yang Chen; Xiaolong Liu
Journal:  Stem Cell Res Ther       Date:  2020-08-08       Impact factor: 6.832

Review 9.  Mechanisms of Key Innate Immune Cells in Early- and Late-Onset Preeclampsia.

Authors:  Ingrid Aneman; Dillan Pienaar; Sonja Suvakov; Tatjana P Simic; Vesna D Garovic; Lana McClements
Journal:  Front Immunol       Date:  2020-08-18       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.